To include your compound in the COVID-19 Resource Center, submit it here.

Stemline's SL-401 meets in Phase II for BPDCN

Stemline Therapeutics Inc. (NASDAQ:STML) gained $3.10 (29%) to $13.65 on Tuesday after it said SL-401 met the primary endpoint in a pivotal Phase II trial to treat blastic plasmacytoid

Read the full 299 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE